Versant Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$38.4K Buy
2,556
+1,404
+122% +$33.7K ﹤0.01% 1592
2026
Q2
$38.5K Buy
1,152
+1,001
+663% +$24.9K ﹤0.01% 1542
2026
Q1
$3.16K Sell
151
-523
-78% -$11.8K ﹤0.01% 2482
2025
Q4
$15.5K Buy
674
+243
+56% +$7.99K ﹤0.01% 1791
2025
Q3
$13K Buy
431
+127
+42% +$3.81K ﹤0.01% 1820
2025
Q2
$11.1K Buy
304
+130
+75% +$4.69K ﹤0.01% 1849
2025
Q1
$6.3K Buy
174
+15
+9% +$624 ﹤0.01% 1937
2024
Q4
$6.69K Buy
159
+81
+104% +$4.02K ﹤0.01% 1611
2024
Q3
$4.33K Hold
78
– – ﹤0.01% 1341
2024
Q2
$3.21K Buy
+78
New +$3.33K ﹤0.01% 1363
2023
Q3
– Sell
-12
Closed -$554 – 2034
2023
Q2
$554 Buy
+12
New +$557 ﹤0.01% 1810

Other funds holding RARE

Versant Capital Management's RARE Position: Q3 2026 in Review

Versant Capital Management increased its Ultragenyx Pharmaceutical (RARE) stake by 122% in Q3 2026, buying an estimated $33.7K and bringing the position to 2,556 shares worth $38.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1592.

Versant Capital Management first reported a position in RARE in Q2 2023 and has held it in 11 quarters since. The position peaked at $38.5K in Q2 2026. 268 funds tracked by Wall St. Rank hold RARE as of Q3 2026.

  • Versant Capital Management held 2,556 shares of Ultragenyx Pharmaceutical worth $38.4K as of Q3 2026.
  • Versant Capital Management bought 1,404 Ultragenyx Pharmaceutical shares in Q3 2026, an estimated $33.7K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #1592 holding.
  • Versant Capital Management first reported a position in Ultragenyx Pharmaceutical in Q2 2023 and has held it in 11 quarters since.
  • Versant Capital Management's Ultragenyx Pharmaceutical position peaked at $38.5K in Q2 2026.
  • 268 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2026.

Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.